Phase II
The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.
Now that most people in North America and Europe are vaccinated and the COVID-19 pandemic is diminishing, Moderna is looking for its second act.
An AstraZeneca/Merck combination showed mostly positive ovarian cancer data, Adaptimmune posted a strong ORR in solid tumors and BioNTech revealed data from a CAR-T cell therapy.
The ESMO conference is serving as a post-mortem on the trials that sunk the multi-billion-dollar partnership between Bristol-Myers Squibb and Nektar Therapeutics.
Biogen announced that its mid-stage monoclonal antibody litifilimab is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.
There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.
SpringWorks, Eli Lilly, EMD Serono and Mirati released data ahead of the European Society of Medical Oncology (ESMO) 2022 Meeting in Paris.
BioVie announced topline results from a Phase II biomarker study in Alzheimer’s disease showing patient improvements in cognition and reductions in neural inflammation.
Wednesday evening, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 7-2 to recommend approval of Amylyx ALS candidate AMX0035.
Gilead, Merck, Daiichi Sankyo, HUTCHMED and BMS previewed data to be presented at the European Society for Medical Oncology Congress 2022, taking place Sept. 9-13.
PRESS RELEASES